-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a ...
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based ...
-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro anti-viral activity assay systems- -Previously announced SPAC ...
SEOUL, South Korea, Nov. 2, 2021 /PRNewswire/ -- From the 18th of October to the 27th of December, Shincheonji Church of Jesus (SCJ), the Temple of the Tabernacle of the ...
Copyright © 2015 - 2021 Lifecarenews.in
